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Abstract 
	 The	human	carboxylesterase	1	or	CES1	is	an	enzyme	predominantly	expressed	in	the	liver	where	
numerous	hydrolytic	reactions	take	place.	It	is	believed	that	this	enzyme	is	responsible	for	approximate-
ly	80%	of	hydrolytic	activity	in	the	liver	and	leaves	the	rest	of	20%	to	its	counterpart	enzyme,	human	
carboxylesterase	2	(CES2).	CES1	plays	a	critical	role	in	hydrolysis	of	numerous	compounds	which	contain	
ester-	and	amide-bonds,	including	drugs,	prodrugs,	endobiotics,	and	xenobiotics.	Owing	to	its	significant	
role,	extensive	studies	have	been	carried	out	to	investigate	its	gene	structure	and	polymorphisms,	protein	
structure	and	function	as	well	as	many	other	aspects.	The	present	review	highlights	the	importance	of	
the	structure	of	CES1	in	regard	to	its	function	and	catalytic	activity.	Additionally,	it	was	found	that	CES1	
catalytic	activity	can	be	influenced	by	variations	or	SNPs	in	DNA	coding	region,	promoter	region	as	well	as	
5’	untranslated	region	of	CES1.	These	alterations	in	the	catalytic	activity	of	an	enzyme	have	been	shown	
to	associate	with	clinical	outcomes.	Therefore,	polymorphisms	related	to	functional	activity	of	CES1	in	the	
hydrolysis	of	drugs	and	prodrugs	are	also	discussed.	
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 Gene structure and classification of 
Carboxylesterases
 Mammalian carboxylesterases (CESs) are 
members of the serine hydrolase superfamily which 
catalyze the hydrolysis of amide, ester, and carbamate 
bonds. They are found in various mammals and 
exhibit broad substrate specificity. Carboxylesterases 
play an important role in the metabolism of numerous 
compounds, including xenobiotics and endobiotics. 
CESs can be classified into six families, namely CES1-
CES6, according to their sequence identity in which 
members in the same family share sequence identity of 
60% or higher. Among these families, CES1 is the largest 
family, containing 8 subfamilies1. On the other hand, 
based on the molecular and bioinformatics data, human 
genome comprises seven distinct carboxylesterase 
genes. They are assigned to CES1, CES2, CES3, CES5, 
and CES6 families and found to share sequence identity 
of 39–46%2,3. CES1 is predominantly expressed in the 
liver but is also found in various tissues including heart, 
testis, macrophages, and lung and is responsible for 
drug and prodrug metabolism and activation including 
endobitotics and xenobiotics hydrolysis4-6. CES1 has 
three members which are CES1A1, CES1A2, and 
CES1A3. Only CES1A1 and CES1A2 are functional 
where CES1A3 is an alternate form of CES1A2 
containing a premature stop codon7,8. The difference 
between CES1A1 and CES1A2 is found in the signal 
peptide region where four amino acids are divergent, 
therefore, both CES1A1 and CES1A2 encode identical 
mature proteins7. On the other hand, CES2 is mainly 
expressed in intestine and has been demonstrated to be 
efficient in the hydrolysis of various compounds such as 
anticancer prodrug and cocaine9. Although both CES1 
and CES2 are major hydrolytic enzymes responsible for 
hydrolysis of several therapeutic compounds, they differ 
in substrate preferences. CES1 favours small alcohol 
and large acyl group substrate whereas CES2 prefers 
substrate with large alcohol and small acyl group10. The 
third human carboxylesterase, CES3, is expressed in 
several tissues particularly colon, trachea, and brain 
tissue. Scant information is however available regarding 
the characterization and substrate specificity of this 
CES3. It is believed that CES3 participates in colon and 
neural drug metabolism11. CES5 is mainly expressed 
in peripheral tissues, including kidney, testis, brain, 
and lungs. It is a secreted protein and its function is to 
regulate the pheromone precursor production and to 
participate in lipid and cholesterol transfer processes12. 
The final member of human carboxylesterse, CES6, also 
known as CES4A also encodes a secreted enzyme that 
is responsible for detoxification of drugs and xenobiotics 
in neural and other tissues13. 
 Structure of human CES1
 CES1 belongs to an α/β-hydrolase-fold protein 
which contains a unique arrangement of alternate 
α-helix and β-sheets connected by loops with various 
lengths14. It shares similar structure to other members 
of α/β-fold enzymes such as acetylcholinestererase15. 
Currently, five crystal structures of human CES1 
in complex with different compounds have been 
determined16-20. Overall, the crystal structures of CES1 
exhibited an α/β-hydrolase-fold in which one monomer 
is formed by 17 α-helices and 20 β-strands, consisting 
of three domains which are central catalytic domain, 
surrounding by an αβ domain and a regulatory 
domain. The serine hydrolase catalytic triad consisting 
of Ser221, Glu354, and His468 is located at the base of 
the active site gorge in the central catalytic domain of 
the protein which is composed of strands β1–9, β12–13, 
and β16–19 and helices α1–5, α9 and α13–15. 
The αβ domain contains α6–8, β10–11 and β14–15 
while regulatory domain consists of α10–12, α10’, and 
α16. It was also shown in the structure that CES1 has a 
conserved N-linked glycosylation site at Asn79 which is 
believed to help in protein folding, solubility, and trimer 
stabilization. Moreover, glycosylation at Asn79 is also 
important for the function of the enzyme18.
 Additionally, the crystal structures have 
indicated that CES1 enzyme actually contains three 
ligand binding sites which are the active site, side door, 
and Z-site. The active site is settled at the bottom of a 
catalytic gorge and aligned in a serine esterase typical 
character19. In fact, the substrate-binding gorge of the 
enzyme consists of two pockets; one is large and flexible 
located on the one side of Ser221 while the other one is 
rather small and rigid sitting on the opposite side. The 
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larger binding site provides flexibility as well as comfort 
to promote the binding towards various substrates 
for the enzyme, causing the promiscuous activity of 
CES1. The second ligand binding site, the side door, 
is a secondary pore that leads into the enzyme’s active 
site from the exterior, located adjacent to the large and 
flexible substrate-binding pocket. It has been proposed 
that this opening allows the direct access of ethanol to the 
acyl-enzyme intermediate during the transesterification 
of cocaine. Therefore, the function of this side door is to 
shuttle small molecules into and out of the active site of 
the enzyme. Finally, the Z-site located on the surface of 
the enzyme, is crucial for trimer-hexamer equilibrium of 
the enzyme16. In hexamer form, two trimers are stacked 
with their substrate-binding gorge facing in, an creating 
extensive dimer interface which results in interdigitation 
of two loops (Ω1 and Ω2) and creates a Z-shape dimer 
interface or Z-site16,17. It was found during olimerization 
analysis of CES1 using atomic force microscopy (AFM) 
that the presence of ligand analogue, homatropine, 
moves the trimer-hexamer equilibrium toward the 
trimer form. With the ligand bound in Z-site, the site is, 
therefore, not available for interacting with another trimer, 
hindering the packing of two trimers to form a hexamer. 
Consequently, binding of ligand to Z-site causes the 
shift of the trimer-hexamer equilibrium and Z-site is 
accessible for the ligand only when enzyme is in the 
trimer form17. The movement of equilibrium toward trimer 
form apparently promotes the binding of substrate to the 
enzyme binding site as well as enhances catalysis. It 
has been observed that various types of ligands could 
bind to the Z-site of CES1, suggesting the promiscuity 
of this site. This feature also reflects the promiscuous 
activity of the enzyme as CES1 is able to catalyze a 
wide variety of substrates. Furthermore, the structural 
analysis and kinetic data of CES1 have suggested that 
Z-site is also important for the function of the enzyme in 
which this site plays direct role in the allosteric activation 
of catalysis.
 Role of CES1 in drug, prodrug metabo-
lism, and activation
 CES1 is predominantly expressed in the liver 
where it plays important role in the metabolism of a wide 
variety of compounds containing ester bonds, including 
drugs, prodrugs, and xenobiotics21,22. Additionally, 
CES1 is known to catalyze endobiotics such as those 
associated with cholesterol and fatty acid homeostasis23. 
In fact, CES1 favourably hydrolyses substrate with small 
alcohol group and a large bulky acyl group which is 
in contrast to CES2 where a large alcohol and small 
acyl group is preferred. In this review, metabolism and 
activation of drug and prodrug by CES1 will be focused. 
 Immunosuppressant agents
 Inosine monophosphate dehydrogenase 
(IMPDH) is the rate-limiting enzyme in de novo pathway 
of guanine nucleotide biosynthesis. This enzyme is 
important for DNA, RNA, and glycoprotein synthesis, 
cell signalling pathway, including processes involved 
in cellular proliferation. The enzyme has therefore been 
proposed as a drug target for immunosuppressive and 
cancer chemotherapy. Mycophenolic acid (MPA), an 
immunosuppressant agent, is the active metabolite 
of ester prodrug, mycophenolate mofetil (MMF). It 
is a noncompetitive inhibitor of IMPDH. Fujiyama et 
al. have studied the hydrolysis of MMF by CES1 and 
CES2 and found that both human carboxylesterase 
can hydrolyse this ester prodrug, resulting in an active 
metabolite MPA24. However, CES1 catalysed the 
reaction approximately 10-fold faster than that of CES2, 
suggesting that CES1 is the main enzyme responsible 
for the activation of MMF prodrug in the liver. Since MMF 
is orally administered and encountered the intestine 
before the liver, MMF hydrolysis by CES2 might have 
occurred as well. Therefore, the detailed study of both 
enzymes regarding MMF metabolism is required and 
would be important to provide useful information for 
understanding the pharmacokinetics of this drug. 
 Anaesthetics
 There has been reported that CES1 can 
hydrolyse amide-type local anaesthetics, prilocaine 
and lidocaine25.  The lidocaine/prilocaine combination 
(equal in weight) is used to prevent pain associated with 
intravenous catheter insertion, blood collection, and 
superficial surgical procedures. The mixture is commonly 
used in dentistry. Hydrolysis of prilocaine results in 
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the aromatic amine o-toluidine while metabolism of 
lidocaine gives 2, 6-xylidine. Although both metabolites 
are suspected to be involved in methaemoglobinemia. 
Lidocaine/prilocaine combination however is still safe 
to use in patients. This study has provided evidence 
regarding the importance of CES1 in drug toxicity.
 Antihypertensive agent
 Prodrug trandolapril is an inhibitor of the 
angiotensin-converting enzyme (ACE) and is currently 
used in clinical treatment of hypertension. Trandolapril, 
itself, is a weak ACE inhibitor and, therefore, requires a 
biotransformation to its active metabolite, trandoprilate26. 
It is believed that the bioactivation of trandolapril to its 
active metabolite occurrs in the liver. Trandoprilate 
illustrates a greater inhibition activity of approximately 
8 folds against ACE when compared to its parent 
compound. In the study where hydrolysis of trandolapril 
was determined by in vitro incubation with human liver 
microsomes where CES1 is abundantly expressed and 
human intestine microsomes where CES2 is predominant, 
it was found that trandolapril was hydrolysed only by 
liver but not intestine microsomes. Additionally, cell 
lines stably expressing native CES1 was also efficiently 
catalysed trandolapril. This suggested that CES1 is 
responsible for trandolapril metabolite activation27.
 Antiplatelet agent
 Adenosine-5’-diphosphate (ADP) is an 
important mediator in metabolism and also plays 
crucial role in energy flowing in living cells. One of its 
roles is to be a mediator in blood platelet activation. 
ADP is stored inside blood platelet and released upon 
platelet activation. In this situation, it is acting as primary 
mediator by interacting with ADP receptors on platelet 
which leads to platelet activation. Therefore, inhibition 
of platelet aggregation is critical for treatment of arterial 
occlusive disease, especially for managing patients with 
coronary artery disease and acute coronary syndrome 
(ACS), including patients undergoing percutaneous 
coronary intervention (PCI)28,29. 
 Thienopyridine prodrugs such as ticlopidine, 
clopidogrel and prasugrel, are inhibitors of adenosine-
5’-diphosphate (ADP)-mediated platelet aggregation 
in vivo30,31. Combination of aspirin and clopidogrel 
is widely used as antithrombogenic agents and is 
proven to be successful for treatment and prevention of 
cerebro- and cardio-vascular problems32-34. It was first 
shown by Tang et al. that human CES1 was an enzyme 
responsible for the hydrolysis of clopidogrel and its 
metabolite was identified. On the other hand, aspirin 
was mainly hydrolysed by CES2. Though both CES1 
and CES2 are capable of hydrolysing the transformation 
of prasugrel to its metabolite, R95913, the catalysis rate 
of CES2 seems to be greater than that of CES1 for 25-
fold, suggesting that CES2 is mainly responsible for 
bioactivation of prasugrel35. 
 Psychostimulants
 Methylphenidate (MPH) is commonly considered 
as “gold standard” for managing attention-deficit/
hyperactivity disorder or ADHD. It was found that 
there is a difference of each individual in regarding the 
metabolism and disposition of two enantiomers of MPH, 
l- and d-MPH36. The metabolic pathway governing the 
metabolism of MPH is deesterfication which is mediated 
by CES1 in an enantioselective manner and hydrolysis 
of the l-isomer is favoured over d-isomer37. However, 
pharmacokinetics analysis of MPH has indicated that 
l-isomer is only accounted for small amount of MPH 
circulated in blood while d-MPH is the main species. 
Zhu et al., have reported the enzymatic activity of 
CES1 towards the hydrolysis of p-nitrophenyl acetate 
(pNPA), d-MPH and l-MPH. It was found that WT CES1 
demonstrated notable activity on pNPA hydrolysis. 
In addition, MPH metabolism by WT CES1 showed 
the significant stereospecific with l-MPH favored over 
d-isomer38. These stereoselective manners of CES1 
were in agreement with previous observations39. This 
indicated that CES1 is an enzyme responsible for 
metabolism of MPH. 
 Antiviral agents
 CES1 also plays important role in anti-human 
HIV prodrug activation. This was evident from the 
study by Saboulard et al. in which the metabolism 
of phosphoramidate triester prodrugs of stavudine 
and zidovudine mediated by carboxylesterase was 
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investigated40. Both stavudine and zidovudine are 
nucleoside analogue reverse-transcriptase inhibitor 
(NARTI), active against HIV. They are analogue of 
thymidine which will be phosphorylated by kinase 
into its active triphosphate form. Triphosphate forms 
of stavudine and zidovudine will cause termination 
of DNA replication by competing with their natural 
substrate (thymidine triphosphate) during incorporation 
into the DNA strand. It has been shown that the first 
activation step of these two compounds is mediated by 
carboxylesterase41-43. Additionally, the efficiency of this 
step is dependent on the amino acid, alkyl ester and 
dideoxynucleoside moiety by which amino acid group 
has the most influence on pharmacokinetics of the 
triester as well as associates with the stability. It was 
also revealed that stability of ester derivative provides a 
small advantage in antiviral activity.
 Oseltamivir phosphate, a neuramidinase 
inhibitor, is an ester prodrug which requires a conversion 
into its active metabolite, oseltamivir carboxylate, by 
CES144. It is the main medicine recommended by the 
World Health Organization (WHO) and commonly used 
for the treatment of influenza virus A and B infections45. 
Since the biotransformation of many compounds 
predominantly occurs in the liver it was proposed that 
carboxylesterases are responsible for this action. In a 
clinical study, it was found that the hydrolysis of oseltamivir 
was extremely slow in children who express low levels of 
carboxylesterase enzymes46-48. It was proven later that 
the enzyme responsible for oseltamivir metabolism is 
CES1 rather than CES2. The in vitro assay using liver and 
intestine microsomes as well as recombinant CES1 and 
CES2 enzymes has shown that hydrolysis of oseltamivir 
only occurrs in the presence of liver microsomes and 
recombinant CES1 enzyme. While none of the active 
metabolite, oseltamivir carboxylate, was detectable for 
neither intestine microsomes nor recombinant CES244. 
This strongly indicated that CES1 not CES2 is the enzyme 
responsible for the biotransformation of oseltamivir and 
that the liver is the primary organ where metabolism of 
oseltamivir happens. Furthermore, an investigation on 
the conversion of oseltamivir to its metabolite by using 
two variant enzymes has provided further evidence that 
CES1 is important for activation of oseltamivir49.
 Anticancer agents
 One of the most significant roles of 
carboxylesterase in prodrug and drug biotransformation 
is its function in metabolism of anticancer. At the present, 
many anticancer agents have been investigated and 
CES1 was shown to be responsible for hydrolysis of 
several agents. Brivanib alaninate prodrug is being 
developed for anticancer treatment. It exerts its 
function by inhibiting vascular endothelial growth factor 
(VEGF) and fibroblast growth factor (FGF) signalling 
pathway through the inhibition of tumour-induced 
angiogenesis50,51. It is currently in phase II/III clinical 
studies for the treatment of cancer52. Interestingly, 
brivanib, an active metabolite of brivanib alaninate, 
showed promising activity in both preclinical and clinical 
studies53-55. The hydrolysis of brivanib alaninate prodrug 
was studied and the results have shown that both CES1 
and CES2 can convert brivanib alaninate into its active 
moiety56. However, it is still not possible to rule out that 
other liver esterases are also involved in the hydrolysis 
of this prodrug. Therefore, more information is required 
to examine which esterase is mainly responsible for 
brivanib alaninate activation.
 It was known that cancer cells exhibited 
abnormal DNA methylation patterns which are also 
associated with aberrant silencing of tumour suppressor 
genes57,58. As a consequence, inhibitors of DNA methylation 
have been developed as anticancer treatment. 
Azacytidine (5-aza derivatives of cytosine) is a potential 
inhibitor of DNA methyltransferase and it has been 
going through development to obtain a better anticancer 
activity59. Fortunately, it was found that modification 
of N4 position of the azacitidine ring (NPEOC-DAC) 
can be used to inhibit DNA methyltransferase and is 
more effective than its parent compound, azacitidine, 
at inhibiting DNA methylation at high concentration 
e.g. more than 10 µM.  The study by Byun et al., has 
indicated that the anticancer activity of NPEOC-DAC is 
limited to cells expressing CES160. This indicates that 
carboxylesterase is responsible for the cleavage of the 
N4 carboxylester bond, converting NPEOC-DAC to its 
active metabolite, decitabine. 
 Among anticancer agents, irinotecan or 
CPT-11, a clinically approved anticancer drug, is 
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one of the most widely investigated agent61. Though 
conversion of CPT-11 to its active metabolite SN-38 
has been elucidated in mammal species, enzymes 
responsible for the conversion in human were not clearly 
identified62. Previous reports have shown that tumour 
cells expressing human liver carboxylesterase can 
hydrolyze CPT-11, giving SN-3863-65. In 2000, purified 
human liver carboxylesterase enzymes (CES1 and 
CES2) were investigated for the bioactivation of CPT-
1166. It was found that both CES1 and CES2 were able 
to convert CPT-11 to SN-38, however, CES2 showed 
a greater catalytic activity towards the hydrolysis. This 
was in agreement with other studies where CES2 have 
considerably greater potential for the conversion of 
CPT-11 to SN-3867. It was later investigated that the 
descent activity of CES1 resulted from the size of the 
active site entrance.  With small active site entrance of 
CES1, it cannot accommodate the bulky substrate like 
CPT-11 well when compared to other carboxylesterases 
such as rabbit and intestine CES or CES268. Modelling 
of the kinetic data for bioactivation of CPT-11 fit a two-
enzyme model with a high- and low-affinity isoforms of 
liver carboxylesterases. The role of CES1 in hydrolysis 
of CPT-11 is therefore still unclear. 
 Capecitabine, prodrug of 5-fluorouracil, is an 
approved treatment of metastatic breast and colorectal 
cancers69. It undergoes a three-step activation process 
in which the first step is the hydrolysis of carbamate 
side chain of capecitabine, producing 5’-deoxy-5-
fluorocytidine (5’-DFCR). This step occurs primarily in 
the liver by carboxylesterases70-73. However, a specific 
enzyme responsible for capecitabine hydrolysis has 
not been unequivocally described. Quinney et al. have 
reported the steady-state kinetics analysis of capecitabine 
by purified human carboxylesterase isozymes (CES1A1, 
CES2, and CES3)74. Both CES1A1 and CES2 showed 
promising activity towards capecitabine hydrolysis while 
CES3 exhibited extremely low activity. Nonetheless, 
it was found that catalytic efficiency of CES1A1 for 
capecitabine hydrolysis was slightly greater than that of 
CES2. Earlier, it has been reported that biotransformation 
of capecitabine by crude lysate prepared from human 
liver was 19-fold more efficient than that prepared from 
human intestine71. It is clearly seen that activation of 
capecitabine mainly occurred in the liver and it is likely 
that CES1 is predominantly responsible for capecitabine 
hydrolysis. However, more evidences are needed to 
confirm this hypothesis e.g. the hydrolysis efficiency of 
CES2 towards capecitabine hydrolysis in the intestine.
 Association between CES1 polymor-
phism and its role in drug/prodrug 
metabolism
 In addition to study the role of CES1 in drug 
and prodrug metabolism, investigation of the clinical 
significance of CES1 genotypes is also critical to fully 
understand its function. This is owing to the fact that 
alterations in carboxylesterase sequences could result 
in an uncertainty in drug metabolism of each individual 
patient. Currently, there are total of 112 variations in 
CES1 gene reported in the NCBI database of single-
nucleotide polymorphisms (dbSNP)75. Among them, 
there are 34 synonymous and 78 nonsynonymous SNPs. 
Since most of SNPs occurred are nonsynonymous it also 
suggests that these nucleotide alterations might have 
an effect on the enzymatic activity of CES1. Apparently, 
SNPs were not only found in the coding region of CES1 
but also in introns, 5’-unstranslated region as well as 
promoter region. 
 Previously, it was found that transcriptional 
level of CES1 increases when there were variations in 
exon 1, indicating that polymorphisms in the upstream 
region might associate with the expression levels.  In 
the study of Japanese hypertensive populations, it was 
observed that SNP at position -816 (promoter region, 
A>C) of CES1 had influenced the reduction in blood 
pressure when imidapril was used in the treatment76. This 
indicates that this SNP is important for promoter activity 
of the gene in which it has an effect on the transcriptional 
activity, enhancing CES1 expression as well as imidapril 
efficacy. Additionally, SNP at position -816 was found to 
be associated with several other SNPs in the proximal 
promoter regions, generating two additional binding 
sites for Sp1 (specificity protein 1 transcriptional factor). 
It was suggested that these two extra Sp1 binding sites 
are associated with increase transcription of CES177.
 Though it was found that CES2 activity 
toward anticancer CPT-11 is much higher than that of 
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CES161,66, the common SNPs of CES2 found in Japanese 
population does not show any significant effects on 
irinotecan pharmacokinetics. The previous report on 
CES2 polymorphisms in Japanese population has 
indicated that there were only minor genetic variations 
which were associated with lower expression/function of 
CES2 in vivo and in vitro78,79.  Since CES1 is significantly 
expressed in the liver where drug and prodrug 
metabolism occurs, therefore, it is likely that genotypes 
of CES1 might associate with plasma concentration of 
metabolites, including SN-38, the active metabolite of 
anticancer irinotecan. A pharmacogenomic analysis of 
both CES1 and CES2 in 120 people revealed 16 SNPs 
in CES1 gene by which 2 of them were nonsynonymous, 
other 2 were SNPs in the 5’-unstranslated region and 
12 were intronic SNPs (80). No significant association 
between CES1 polymorphisms and RNA expression was 
observed. However, it would be necessary to perform 
functional analysis of these known polymorphisms 
because it will provide useful information regarding their 
roles in protein expression and enzymatic activity.
 A study in cancer patients led by Sai et al. also 
in Japanese populations, has detected four other novel 
variations, one in the 5’-unstranslated region and three in 
5’-flanking region of CES (-285C>T, -233C>A, -161A>G, 
-30G>A) (81). The effects of SNPs on irinotecan 
metabolism were examined. It was found that -75G>T 
SNP increased the AUC ratio while no significant impact 
of -30G>A was observed. The frequency of other three 
novel SNPS was quite low, making it difficult to assess 
the statistical analysis. This would require large samples 
to obtain the clinical importance of CES1 genotyping 
in irinotecan treatment. Interestingly, the in vivo CES 
activity was expanded depending on the number of 
functional CES1 genes, indicating a partial but critical 
role of CES1 on activation of irinotecan. 
 The effect of CES1 genetic polymorphisms on 
the pharmacokinetics of oseltamivir, an anti- influenza 
prodrug, was also examined in healthy Japanese 
male and female by Suzaki et al82. It was found that 
CES1 genotypes had no significant effect on the 
pharmacokinetic parameter of oseltamivir. In addition, 
there was no correlation between number of functional 
CES1 genes and oseltamivir metabolism. It should be 
noted that CES1 variants in studied were alterations in 
exon 1 only; therefore, it is still inconclusive to clarify 
the involvement of individual CES1 polymorphism in 
oseltamivir metabolism based on this study only. Also, it 
is possible that other proteins e.g. organic transporter 3 
and multidrug resistance-association protein as well as 
other mutations in CES1 are associated with metabolism 
of oseltamivir. Previously, two nonsynonymous variants 
in CES1 coding region, Gly143Glu in exon 4 and a 
deletion in exon 6 resulting in frameshift mutation 
(Asp260fs) which altered the following 39 amino acids, 
have been identified and it was found that both mutations 
significantly altered the hydrolytic activity of CES183. The 
supernatant collected from cell lines stably expressing 
native as well as two mutants were studied in which 
the hydrolysis of oseltamivir was assessed. It has been 
shown that the biotransformation of oseltamivir was 
remarkably impaired in both CES1 variants, Gly143Glu 
and Asp260fs. Reduction of about 75% in Vmax and an 
increase of approximately 2-fold of KM were observed 
for Gly143Glu polymorphism towards the hydrolysis of 
oseltamivir. Interestingly, Asp260fs mutant was unable 
to produce any detectable amount of oseltamivir 
metabolite using HPLC analysis, indicating the complete 
activity loss of this variant. The substantial decreased 
activity of both CES1 variants, especially Asp260fs, 
suggests the possibility of oseltamivir treatment failure. 
Fortunately, the prevalence of Asp260fs mutation was 
extremely low, none of the 925 subjects carried this 
mutation in CES1 genotypic analysis. Its effect on 
oseltamivir activation would therefore be only minor. 
However, cautions should have been taken during the 
treatment of influenza infections using oseltamivir.
 In fact, two natural variants, Gly143Glu and 
Asp260fs, were identified during the investigation of the 
interaction of psychostimulant methylphenidate (MPH) 
and alcohol in 20 normal volunteers. One white male 
subject exhibited a highly abnormal concentration versus 
time, suggesting that his CES1 might be defective83. 
DNA sequencing of his CES1 gene has revealed two 
SNPs, Gly143Glu and Asp260fs. In a later study, the 
frequency of these two variants in specific racial and 
ethnic groups was determined38. It was observed that 
Gly143Glu is common with the frequency of 3.7%, 4.3% 
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and 2.0% in white, black, and Hispanic population, 
respectively. On the other hand, Asp260fs happens to 
be a rare mutation with a frequency significantly lower 
than 1% because none of 925 subjects exhibited this 
genotype. In addition, the catalytic activity of these two 
variant enzymes towards the hydrolysis of MPH was 
also assessed. Dramatically decrease catalytic activity 
was observed for both mutants towards the hydrolysis 
of pNPA. It was found that WT enzyme preferred to 
hydrolyze l-MHP isomer over d-MPH for about 10 
times. Expectedly, both mutant enzymes showed no 
measurable catalytic activity toward MPH.  These two 
identified variants have resulted in completely loss 
of CES1 activity and this may be the cause the poor 
response as well as adverse events in MPH treatment.
 Other studies have been carried out to 
investigate the role of two CES1 variants, Gly143Glu 
and Asp260fs, in metabolism of different compounds. 
Incubation assay of cell lines stably expressing WT as 
well as natural mutants was performed for trandolapril 
and pNPA27. The hydrolytic activity of both variants 
was significantly decreased for the hydrolysis of pNPA. 
Gly143Glu exhibited only 30% activity when compared 
to the native CES1 while Asp260fs hardly catalysed the 
hydrolysis of pNPA substrate. Importantly, it was found 
that catalytic activity of both mutants towards trandolapril 
was undetectable, suggesting the significance role of 
these two SNPs relative to the clinical response and 
potential adverse effects associated with trandolapril 
pharmacotherapy.
 Since there were reports of numerous CES1 
polymorphisms from many laboratories as well as the 
database of SNP from NCBI, Tang et al., have assessed 
the influence of natural variants of CES1 on the hydrolysis 
of clopidogrel34. It was found that most of mutant 
enzymes tested in the study showed similar activity 
on the hydrolysis of clopidogrel to the native enzyme. 
Importantly, among 7 CES1 variants, only Cys70Phe 
exhibited lower expression level than other variants 
and also lost catalytic activity toward the hydrolysis of 
clopidogrel. Another study of clopidogrel hydrolysis by 
two CES1 variants (Gly143Glu and Asp206fs) has shown 
that these two mutants were completely inactive84. 
On the other hand, other natural variants, Gly18Val, 
Ser82Leu, and Ala269Ser have no significant effect on 
the hydrolysis of clopidogrel and its derivative, 2-oxo-
clopidogrel.  They suggested that two inactive mutants 
may be responsible for higher plasma concentration 
of clopidogrel-active metabolite and promote the 
antiplatelet activity. This indicates that genetic 
polymorphism of CES1 may relate to pharmocokinetics 
of clopidogrel and, as a consequence, the efficacy of its 
treatment.
 Conclusions
 Recently, enzymes responsible for drug and 
prodrug metabolism receive much attention from 
researchers. It is crucial that biotransformation of these 
compounds occur to produce the active metabolites 
otherwise these drugs would be unable to exert their 
pharmaceutical effects. Among numerous enzymes, 
carboxylesterases are in particular interest because it 
was found that approximately 80% of hydrolytic activity 
manifests in the liver and CES1 is responsible for that 
action while the rest of 20% belongs to CES2, mainly 
expressed in intestine. Owing to the critical role of 
CES1, its structure, function as well as polymorphisms 
associated with drug/prodrug metabolism have been 
extensively investigated. The structural studies of CES1 
exhibited the α/β-hydrolase fold protein, composing 
three domains which are central catalytic, α/β and 
regulatory domains. The active site contains catalytic 
triad (Ser221, His468 and Glu354) located at the base of 
active site gorge. CES1 also has a conserved N-linked 
glycosylation at Asn79 which is believed to be important 
for its function. Additionally, its promiscuity towards 
various substrates was proposed to be the result of large 
and flexible binding site, providing the comfortableness 
for substrate binding. Polymorphism in genes encoding 
enzymes responsible for drugs/prodrug activation has a 
significant impact on patient treatment. If rare mutations 
are observed for the responsible enzyme, a predictable 
clinical response would be expected. However, if 
the genes show high mutation rate especially those 
associated with defective enzyme it would absolutely 
have an influence on drug metabolism. This could 
lead to therapeutic failure as well as unanticipated 
adverse effects or toxicities of the drugs. Fortunately for 
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CES1, most of the common variants studied so far still 
functional with in vitro catalytic activity assay showed 
comparable activity to that of WT enzyme. Exception 
has been made for two critical SNPs, Gly143Glu and 
Asp260fs, both of them demonstrated a significant 
decreased in hydrolysis towards various substrates e.g. 
pNPA, oseltamivir, MPH, and trandolapril. Gly143Glu, a 
common variant, is still able to catalyse the hydrolysis of 
drugs with remaining activity of approximately 25-30% 
when compared to the native enzyme. Though Asp260fs 
mutation results in completely loss of enzymatic activity, 
the frequency of this SNP is extremely low. Problems 
associated with clinical failure and adverse effects would 
therefore be only very minor. However, it would be of 
great importance to be able to screen the polymorphism 
before drug administration. Furthermore, functional 
analysis of each CES1 polymorphism will be useful to 
investigate its role in mRNA and protein expression as 
well as its catalytic activity. This investigation would be 
necessary to uncover the origin of distinct differences 
in drug and prodrug metabolism by variants of CES1. 
Nonetheless, it requires much work and effort.
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